Education
About Us
Working with TipRanks
Follow Us
Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
RESEARCH TOOLSreports
Total Valuation
Rohto Pharmaceutical Co has a market cap or net worth of $482.54B. The enterprise value is ¥563.69B.
Market Cap$482.54B
Enterprise Value¥563.69B
Share Statistics
Rohto Pharmaceutical Co has 236,178,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding236,178,310
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rohto Pharmaceutical Co’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.41%.
Return on Equity (ROE)0.12
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)8.41%
Return on Capital Employed (ROCE)0.12
Revenue Per Employee42.52M
Profits Per Employee4.27M
Employee Count7,259
Asset Turnover0.73
Inventory Turnover2.26
Valuation Ratios
The current PE Ratio of Rohto Pharmaceutical Co is 16.43. Rohto Pharmaceutical Co’s PEG ratio is 0.96.
PE Ratio16.43
PS Ratio0.00
PB Ratio3.02
Price to Fair Value1.96
Price to FCF30.07
Price to Operating Cash Flow20.44
PEG Ratio0.96
Income Statement
In the last 12 months, Rohto Pharmaceutical Co had revenue of 308.63B and earned 31.00B in profits. Earnings per share was 136.11.
Revenue308.63B
Gross Profit169.38B
Operating Income38.47B
Pretax Income42.33B
Net Income31.00B
EBITDA56.42B
Earnings Per Share (EPS)136.11
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Rohto Pharmaceutical Co pays an annual dividend of ¥17, resulting in a dividend yield of 1.92%
Dividend Per Share¥17
Dividend Yield1.92%
Payout Ratio12.49%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-33.94%
50-Day Moving Average2.21K
200-Day Moving Average2.72K
Relative Strength Index (RSI)41.58
Average Volume (3m)1.53M
Important Dates
Rohto Pharmaceutical Co upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Rohto Pharmaceutical Co as a current ratio of 2.30, with Debt / Equity ratio of 5.58%
Current Ratio2.30
Quick Ratio1.65
Debt to Market Cap0.10
Net Debt to EBITDA-0.48
Interest Coverage Ratio40.53
Taxes
In the past 12 months, Rohto Pharmaceutical Co has paid 11.38B in taxes.
Income Tax11.38B
Effective Tax Rate0.27
Enterprise Valuation
Rohto Pharmaceutical Co EV to EBITDA ratio is 8.55, with an EV/FCF ratio of 17.33.
EV to Sales1.56
EV to EBITDA8.55
EV to Free Cash Flow17.33
EV to Operating Cash Flow13.07
Balance Sheet
Rohto Pharmaceutical Co has $61.71B in cash and marketable securities with ¥38.81B in debt, giving a net cash position of -$22.91B billion.
Cash & Marketable Securities$61.71B
Total Debt¥38.81B
Net Cash-$22.91B
Net Cash Per Share-$96.99
Tangible Book Value Per Share$945.43
Margins
Gross margin is 57.58%, with operating margin of 12.46%, and net profit margin of 10.05%.
Gross Margin57.58%
Operating Margin12.46%
Pretax Margin13.72%
Net Profit Margin10.05%
EBITDA Margin18.28%
EBIT Margin14.02%
Analyst Forecast
The average price target for Rohto Pharmaceutical Co is $2,470.66, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2,470.66
Price Target Upside20.99% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast13.95%
EPS Growth Forecast0.37%